Gsk (GSK) Long-Term Deferred Tax (2009 - 2026)

Gsk (GSK) has 10 years of Long-Term Deferred Tax data on file, last reported at $8.7 billion in Q4 2025.

• In Q4 2025, Long-Term Deferred Tax changed 0.0% year-over-year to $8.7 billion; the TTM figure through Dec 2025 stood at $8.7 billion (changed 0.0% YoY), while the FY2025 annual figure was $8.7 billion, changed 0.0% from the prior year.
• Long-Term Deferred Tax held at $8.7 billion in Q4 2025, from $8.7 billion in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $8.7 billion in Q4 2025 and bottomed at $6.6 billion in Q4 2022.
• A 5-year average of $7.7 billion and a median of $7.5 billion in 2023 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2021 — Long-Term Deferred Tax climbed 24.26% — and 2022, when it retreated 5.65%.
• Year by year, Long-Term Deferred Tax stood at $7.0 billion in 2021, then slipped by 5.65% to $6.6 billion in 2022, then gained by 13.13% to $7.5 billion in 2023, then rose by 15.52% to $8.7 billion in 2024, then gained by 0.0% to $8.7 billion in 2025.
• The last three Long-Term Deferred Tax figures came in at $8.7 billion (Q4 2025), $8.7 billion (Q4 2024), and $7.5 billion (Q4 2023), per Business Quant data.

Peer Comparison